Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Vertex Pharmaceuticals Incorporated VRTX

Healthcare  —  Biotechnology
526.19 3.81 0.73% as of 25 Sep
Market cap
$132.3B
P/E
30.4×
S&P 500 Member Revenue Champion (10y)
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Vertex Pharmaceuticals Incorporated (VRTX) EV/EBITDA

As of 25 September 2026, Vertex Pharmaceuticals Incorporated (VRTX) trades at a EV/EBITDA of 25.2×. Over the past ten years it has ranged from 0.0× (June 2025) to 938× (June 2018); the current reading is higher than 63% of that period. That is above the Biotechnology industry median of 0.7× and above the Healthcare sector median of 10.4×.

EV/EBITDA, daily

Annual

Period EV/EBITDA Change
FY2025 25.0× —
FY2024 0.0× —
FY2023 23.7× 67.68%
FY2022 14.1× (17.22%)
FY2021 17.1× (8.47%)
FY2020 18.7× (54.07%)
FY2019 40.6× (27.88%)
FY2018 56.3× (71.78%)
FY2017 200× (19.40%)
FY2016 248× —

Quarterly

Period EV/EBITDA Change
Jun 2026 23.7× 8.99%
Mar 2026 21.7× (13.05%)
Dec 2025 25.0× 11.46%
Sep 2025 22.4× (14.49%)
42 more quarters

Against its own ten years

Low 0.0× High 938×
Ten-year median 19.9×
Current reading's percentile 63

EV/EBITDA against peers

Company EV/EBITDA
INSM Insmed, Inc. compare n/m
RVMD Revolution Medicines, Inc. compare n/m
MRNA Moderna, Inc. compare n/m
REGN Regeneron Pharmaceuticals, Inc. compare 17.3×
RPRX Royalty Pharma PLC compare 22.0×
VRTX Vertex Pharmaceuticals Incorporated 25.2×
ALNY Alnylam Pharmaceuticals, Inc. compare 30.3×
ONC BeOne Medicines Ltd. - Sponsored ADR compare 34.1×
ARGX argenex SE compare 35.1×
Biotechnology industry median 0.7×
Healthcare sector median 10.4×
Market median 11.0×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on VRTX